Original Research ARTICLE
Comparison of Cardiovascular Medicines Prices in Four European Countries
- 1Faculty of Pharmacy Bulgaria, Medical University of Sofia, Sofia, Bulgaria
- 2National Council on Pricing and Reimbursement of Medicinal Products, Sofia, Bulgaria
- 3Economics of Infrastructure Faculty, University of National and World Economy, Sofia, Bulgaria
The aim of the current study was to compare pricing methodologies at the manufacturer, wholesale, and retail levels, and to estimate the price differences of AT1-receptor blockers (sartans), Angiotensin-converting enzyme (ACE)—inhibitors, and their fixed-dose combinations (FDCs) in four countries using similar methodologies: Slovakia, Greece, Bulgaria, and Romania (SK, GR, BG, and RO, respectively). The methodologies for manufacturer, wholesale, and retail price establishment have been compared using nationally implemented rules. Overlapping trademarks were established retrospectively on the manufacturer and retail levels in November 2017. The average price per tablet, percentage of price deviation, and statistically significant differences were calculated. The selected countries apply external reference pricing at the manufacturer level. A wide variation in the number of referent countries was observed (from 12 to 27). Despite the use of a regressive scale for price calculation, large variations between margins and value-added tax (VAT) are established, thus leading to different final medicine prices. This study found that medicine prices were lower in RO than in other selected countries. It was caused by the fact that 15 products had the lowest manufacturer price and 14 products had the lowest retail price in RO. Results of Kruskal–Wallis test showed that there were no significant differences between prices per tablet on the manufacturer and retail levels. In the group of fixed-dose combinations, ramipril/hydrochlorothiazide, and irbesartan/hydrochlorothiazide showed more than 100% deviation. The prices of cardiovascular medicines differed within the observed countries. The differences in pricing methodologies (e.g., margins, VAT) at the national level did not significantly affect retail prices, as a low manufacturer price usually leads to a low retail price.
Reference pricing is used as a method for price regulation in many European countries. Pharmaceuticals prices can be regulated, or can be a result of the market environment (1). The application of external reference pricing (ERP) started in the early the 90's (2), and is now the most commonly used price control measure in Europe (3). In each country, it is applied differently, usually in combination with other pharmaceutical policy measures. The size of the reference basket and the applied rules for a price calculation influence the price level and supply of medicines (4). Pricing criteria implemented in the CEE countries are similar and external reference pricing methodology is common in this region (5).
ERP is applied mainly to reimbursable medicines. The number of countries used as references ranges from three in Portugal to 30 in Poland. The pricing criteria used for medicinal products in the central and eastern European (CEE) countries are quite similar. Slovakia is the most frequently referenced country, whereas Cyprus, Iceland, Malta, Luxembourg, and Norway are not as frequently used as reference countries (6).
The methods for defining reference countries vary. Sometimes, the countries should be similar in terms of some characteristics, such as economic or geographical similarity and health system funding. Studies showed that at the national level, after ERP implementation, health expenditures decreased in the short term, as the prices are more likely to decline (7, 8). At the international level, ERP methodology can affect prices in other European countries, resulting in price fluctuations, delay launches, and manufacturers' withdrawal from markets where the price is low (9). Large launch delay to 3 years on average in Eastern Europe is found (10). Pharmaceutical pricing experts from Russia, Asia, Middle East, and South Africa confirm that ERP could be used for pricing decisions, but not as the only mechanism for price regulation (11).
Recent studies have shown that price differences exist across countries (12, 13). In countries with lower gross domestic product (GDP), where the resources are limited, the payers cannot effectively control the prices if ERP is used only as a cost containment measure (14). Studies show that the introduction of generic products with focus only on prices is not as effective as implementing other policies (15). The medicines are unaffordable for many European Union (EU) citizens. This may contribute to non-compliance, adherence, and rising direct and indirect costs (16–18).
In CEE countries, cardiovascular diseases (CVDs) prevalence is higher than in Western, Northern, and Southern European countries. The data showed that in the EU healthcare for CVDs is 53% (€111 billion), productivity loss is 26% (€54 billion), and informal care of people with CVDs is ~21% (€45 billion) of the total costs (19). Adequate access to cardiovascular (CV) medicines benefits the treatment of CVDs and could lead to decreased morbidity and mortality.
The main objectives of the study were as follows:  to explore the methodology of price calculation in four East European countries—Slovakia, Greece, Bulgaria, and Romania (SK, GR,BG, and RO, respectively) at the manufacturer, wholesale, and retail levels.  To compare prices between overlapping medicinal products from the therapeutic groups of AT1-receptor blockers (sartans), ACE inhibitor groups, and their fixed-dose combinations (FDCs) at the manufacturer and retail levels.  To calculate the price deviations from the lowest priced medicinal products to evaluate the overall effect of a market environment and country policy on medicine prices.
Materials and Methods
Within the international cooperation for prices comparison EURIPID the RO, BG, GR, and SK are considered as countries that manage to maintain the lowest possible prices (https://www.euripid.eu/aboutus). This is one of the reasons for their selection (12, 20, 21). The second reason is that they all apply ERP for the regulation of medicine prices. The third reason is that they refer one to another and always are included in their national baskets despite the regulatory changes. The similar methodology for manufacturer price setting and variation in pricing methodology makes them an attractive for comparison.
Comparative analysis between the methodologies for manufacturer and retail price establishment was performed among countries under consideration. Regulatory acts were used as a source of information and published scientific papers (24–27).
The manufacturer and retail prices of overlapping trademarks (produced by the same marketing authorization holder) of AT1-receptor blockers, ACE inhibitors, and their FDCs were collected from the official registers of the observed countries in November 2017 (28–31). Thirty-four overlapping trade names belonging to seven international non-proprietary names (INNs) and 9FDCsare considered for the price comparison analysis.
Price per tablet was calculated for each trademark. All prices were converted in Euro at the exchange rate of 1 euro = 1.956 BGN (Bulgarian Leva) and 1 euro =4.42 RON (Romanian Lei).
The average price per tablet was calculated at the manufacturer and retail levels between the four countries. The difference in the average and lowest prices was determined by deducting the lowest price from the average.
The statistical significance of price differences on the manufacturer and retail levels was examined using the Kruskal–Wallis test.
The percentage of deviation of medicines prices compared with the lowest one was calculated using the formula:
pij -manufacturer/retail price per tablet of the product i in a country j:
Product i—compared INNs
Country j—selected countries.
Comparison of Methods for Price Establishment
The selected countries applied ERP at the manufacturer level, and they refer their prices one to another. At the national level, there were differences and similarities in methodologies, thus leading to differences in the final prices of products (Table 1).
In GR, the manufacturer prices are calculated as the average of the three lowest prices out of the other 27 EU countries in Europe. Since 2016, price revisions have been applied twice per year—May and November. Decisions for the inclusion of new products are made four times annually. The price of generic products was 65% of the price of the reference product (32) (Table 1).
SK applied reference pricing using prices from 27 European countries. The manufacturer price was calculated as the average of the lowest prices in three countries. In SK, the monthly ex-factory price of medicines was officially published, whereas reference price revisions were conducted every 6 months. The maximum price of the first generic product should not exceed 65% of the reference product price (5). Reimbursements list was revised four times annually (33) (Table 1).
In RO, a new pricing methodology has been applied since 2015. The ex-factory price should be the lowest from the 12 reference countries (where BG, SK, and GR are also included). The reference price of generics was 65% of the producer price for innovative drugs. The reference prices were updated once a year (in October) using the latest average exchange rate from RON to EUR (Table 1).
In BG, the ex-factory price may not be higher than the BGN equivalent of the lowest ex-factory price for the same medicinal product in the reference countries (the total number was 17: 10 main and 7 additional reference countries, Table 1). The Positive Drug List (PDL) was revised each month in terms of inclusion, changes, and/or exclusion of medicines. The manufacturer price of the generic products must not exceed 70% of the manufacturer price of the reference product included in the PDL (Table 1) (34).
Comparison of CV Medicine Prices
The number of overlapping trade names and dosage forms of AT1-receptor blockers, ACE- inhibitors, and FDCs with the lowest prices at the manufacturer and retail levels are presented in Table 2. It is evident that the prices of medicines were lower in RO because 15 products had the lowest manufacturer price and 14 products have the lowest retail price in RO, followed by GR.
The lowest and average price per tablet for each overlapping trademark was calculated as follows (Table 3):
Four INNs of ACE inhibitors and 11 FDCs could be compared in all countries, and those are not the first in the class, such as enalapril. By comparing the manufacturer and retail prices of monoproducts in the group of ACE inhibitors, we confirmed that the unit prices were the lowest in RO, followed by GR and BG. The differences between the average and the lowest prices were not significant in terms of monetary cost. Regarding the FDCs, 1 product in RO (hydrochlorothiazide/ramipril 5/25 mg), 1 in SK (quinapril/ hydrochlorothiazide 20 mg/12.5 mg), and 2 in GR possessed the lowest manufacturer and retail prices (indapamide/perindopril 2.5/0.625 mg and indapamide/ perindopril 5/1.25 mg). In the group of AT-receptor blockers, comparison between 4 INNs and 10 FDCs was possible. At the manufacturer and retail levels, the lowest price was found in one product in RO (irbesartan 150 mg). The FDC GR had the lowest manufacturer price for telmisartan/hydrochlorothiazide 80 mg/12.5 mg, and the lowest retail price for irbesartan/hydrochlorothiazide 300/12.5 mg.
Results of Kruskal–Wallis test showed that there were no significant differences between the lowest and average price per tablet on the manufacturer and retail levels (p > 0.05).
Table 4 presents the rate of deviation in percentage from the lowest manufacturer and retail prices in each country (Table 4). Where there was only one product, the rate of deviation was not calculated, which happened often in RO (n = 14). This could mean that in RO, fewer products per INN were reimbursed. Higher rate of deviation in GR showed a wide competition per observed INN, which was most evident for ACE inhibitors.
Within the group of monoproducts, the ACE inhibitor ramipril was the INN with a high price deviation of 241–458%, whereas in the group of AT-receptor antagonists, irbesartan had a deviation of 219–240%.
Between FDCs, prices of combinations of ramipril/hydrochlorothiazide in the group of ACE inhibitors and irbesartan/hydrochlorothiazide in the group of AT-receptor antagonists deviated by more than 100%.
The observed countries applied ERP as a methodology for the control of expenditures, but different calculation methods to compute the prices on a national level. The number of reference countries included in the basket varied from 12 to 27, but the lowest prices did not differ significantly, probably owing to simultaneous referencing at the manufacturing level. GR and SK used an average of three of the lowest prices, whereas BG and RO used the lowest prices from the countries in the basket. These differences in the number of referent countries, as well as the period of price revision, probably determined the differences between pharmaceuticals prices.
There are international collaborations for price comparison for the regulatory purposes as EURIPID for example but studying why some countries manage to maintain the lowest prices if beneficial for the international audience, especially for the medicines with high utilization (35). If the experience of those countries is analyzed and popularized, it will make important medicines affordable to many more citizens in Europe. This online database of EURIPID is currently exclusively available for national competent authorities for pricing and reimbursement of medicinal products that makes the scientific comparison of the methodologies and prices impossible via it.
The effectiveness of ERP measures is now widely discussed. The price revision in one country may contribute to changes in the others. A literature review showed that ERP application as a policy measure depends mainly on implementation and rules within the countries (36, 37). ERP is a well-known and widely used tool to control expenditures, but price control should be used together with other policies, especially those supporting the rational use of medicines and improving prescribing behavior (38).
A systematic review proved that reference pricing reduces pharmaceutical prices and, hence, expenditures and leads to substitution toward lower-priced drugs. This study also confirmed the need for new effective pricing policies, including value-based pricing, managed entry agreements, and health technology assessment (HTA) (39). At the analysis, BG and RO use managed entry agreements (40), whereas HTA is performed in BG, RO, and SK.
Over 2,000 drugs have disappeared from the market in the last 5 years, thus affecting patients' access to therapy and enhancing parallel exports (41, 42). Such a negative tendency can ruin the concept of ERP, which is why such studies are necessary.
A simulation of pharmaceutical prices showed a 15% reduction over 10 years. More detailed country baskets and frequent price revisions lead to higher price reductions. Revision frequencies also varied and contribute to price divergence and international price decrease (43).
The frequent price revision in BG probably led to a high rate of prices decreasing between 4 and 75.4% (44, 45). In GR, an average price decrease of 9.5% was achieved after the changes in the reference price system in 2010. Prices of ~12,000 medicinal products were recalculated because of the new system introduced in 2010 (46). Nevertheless, the study found the most significant deviation (more than 100%) for the six products in GR, thus confirming that other factors, such as the company's policy, taxes, and country environment, also affected the final medicine prices.
The SK new reference pricing system, which was introduced in 2012, was expected to create savings estimated at € 75 million. However, in SK, ERP resulted in higher prices compared with countries with similar income levels owing to the selection of reference countries (8).
A previous study confirmed that there is no substantial reduction in international price differences within EU countries applying EPR (47). We found that a small difference existed between the average and lowest prices, and there was a lack of significant difference in the same trademarks. However, after applying the price deviation approach, we observed large variations in prices between some of the countries. Therefore, the use of different approaches and points of view could provide more comprehensive and objective data of the existing price differences. It could be used by manufacturers and regulatory bodies when determining a price variation between countries. It is also important for receiving information on CV medicine utilization and how it is affected by price variation, a problem for which there is relatively limited information in the country (48).
The observed price deviation varied from 0.1 to 458%, thus confirming that the existing magnitude of the price difference was significant as a value. However, only six medicinal products showed more than 100% deviation from the lowest price. ACE inhibitor prices revealed the highest hesitations, whereas FDCs prices did not differ at such high degrees. Likewise, there were no products found at the same price in two or more countries. The reasons for such variance were probably more related to the health insurance environments and the country policy (49).
A price comparison of high-cost originator medicines in some European countries found lower prices in GR, Hungary, SK, and the UK. German and Swedish, Danish, and Irish prices were found at the upper end (7). Another study showed the highest prices in Germany (9), whereas one of the lowest prices is found in RO. Our study also found the lowest prices of CV medicines in RO (at the manufacturer and retail levels), despite the fact that the list of reimbursed medicines in RO was not updated between 2008 and 2015. Other factors, such as margins, VAT, or exchange rate, lead to low medicine prices.
A previous study on CV medicine prices showed that BG and RO follow the same methodology, but the differences in VAT and margins set different retail prices. The lower wholesale and retail margins in BG lead to a lower retail price, regardless of the higher VAT (20% in BG and 9% in RO). Therefore, the VAT influence is not the one factor for final retail price formation (50). The lower VAT rate has been balanced with higher margins in some countries.
The study found that differences between the prices of CV medicines existed, despite the expectation that ERP would equalize and reduce them. The differences between retail prices in the four countries under consideration were higher than those found at the manufacturer level. This was due to the established mechanisms for calculation of final medicine prices and ERP applications.
Our study confirms ERP methodology limitations and establishes price difference in reference countries, if they are compared simultaneously. This is the first study comparing prices of CV -medicines on manufacturer and retail level and provides direct data for ERP and implemented methodologies influence on final prices. The price comparison is widely discussed issue and often used from pharmaceutical companies for decision of product launches, from regulatory bodies for amendment of legislation or from other researchers reporting implemented regulatory measures for price control. The limitation of the study is a small number of overlapping trade names found (on total 34 in four countries) from overall variety of medicinal products approved in EU. This prompts the necessity for further studies exploring price differences and ERP influence on total medicines market.
Overall, the study found that lower manufacturer prices led to lower retail prices. The deviation in prices revealed their sensitivity to health policies and the market environment. It also contributed to manufacturers' decisions and therapeutic competition within a country.
In summary, the prices of CV medicines differed within the observed countries. The differences in pricing methodologies (e.g., margins, VAT) at the national level could not influence retail prices significantly, as a low manufacturer price usually led to a low retail price. From our results, we can conclude that RO was the country with the lowest prices of CV medicines (AT-receptor blockers and ACE inhibitors), followed by GR owing to financial crisis and low incomes. It could favor patients' affordability and cardiovascular therapy in those countries. Although BG had very frequent price revision as well as the lowest GDP per capita in the EU, this was not the key driver for lower prices, especially at the retail level.
Data Availability Statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: National Council on prices and reimbursement of medicinal products. Registers PDL. Annex 1 https://portal.ncpr.bg/registers/pages/register/archive.xhtml Ministerstvo zdravotníctva; Available at: http://www.health.gov.sk/?kategorizacia-a-ceny Yπoϵργεí Yγεíας/Ministry of health; Available at: http://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn Casa Nationalâ de Asigurâri de Sânâtata/National Health Insurance Fund Available at: http://www.cnas.ro/category/lista-medicamentelor.html.
GP conceived and designed the investigation and collected the data. ZM, AS, and MM prepared medicine selection and price calculations. MV performed a methodology comparison. ST and MM analyzed the data and performed the deviation percentage analysis. ZM performed the statistical analysis. GP designs the result interpretation and discussion. All authors wrote and revised the manuscript, and approved its submission for publication, confirming that that the work is original.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
ACE, inhibitors: Angiotensin-converting enzyme inhibitors; AT1, receptor blockers, sartans: Angiotensin II type 1 receptor blockers; CEE, countries: Central and Eastern European countries; CVD, cardiovascular diseases; ERP, external reference pricing; EU, European Union; FDCs, fixed-dose combinations; INN, International non-proprietary name; PDL, Positive Drug List; VAT, value-added tax.
1. Aho E, Johansson P, Rönnholm G. International Price Comparison of Pharmaceuticals 2016 – A Volume Based Analysis of Swedish Pharmaceutical Prices Relative to 19 Other European Countries. Dental and Pharmaceutical Benefits Agency (2017). p. 5–101.
2. Espin J, Rovira J, de Labry AO. WHO/HAI Project on Medicine Prices and Availability. Review Series on Pharmaceutical Pricing Policies and Interventions. Working Paper 1: External Reference Pricing. World Health Organization and Health Action International (2011).
3. Vogler S, Lepuschütz L, Schneider P, Stühlinger V. Study on Enhanced Cross-Country Coordination in the Area of Pharmaceutical Product Pricing. Final Report. European Commission; Directorate General for Health and Food Safety (2016). p. 1–129. doi: 10.2875/631265
5. Kawalec P, Tesar T, Vostalova L, Draganic P, Manova M, Savova A, et al. Pharmaceutical regulation in central and eastern european countries: a current review. Front. Pharmacol. (2017) 8:892. doi: 10.3389/fphar.2017.00892
7. Leopold C, Vogler S, Mantel-Teeuwisse AK, de Joncheere K, Leufkens HG, Laing R. Differences in external price referencing in Europe—a descriptive overview. Health Policy. (2012) 104:50–60. doi: 10.1016/j.healthpol.2011.09.008
8. Toumi M, Remuzat C, Vataire AL, Urbinati D. External Reference Pricing of Medicinal Products: Simulation-Based Considerations for Cross-Country Coordination. Final Report. Brussels: European Commission (2014).
9. Kanavos P, Fontrier A, Gill J, Efthymiadou O, Boekstein N. The Impact of External Reference Pricing within and across Countries. London, UK: London School of Economics and Political Science (2017). doi: 10.21953/lse.m0bluqcv10g6
10. Holtorf AP, Gialama F, Wijaya KE, Kaló Z. External Reference pricing for pharmaceuticals—a survey and literature review to describe best practices for countries with expanding healthcare. Value in Health Regional Issues. (2019) 19:122–31. doi: 10.1016/j.vhri.2019.04.003
11. Maini L, Pammolli F. Reference Pricing as a Deterrent to Entry: Evidence from the European Pharmaceutical Market. (2017) 1–64. Available online at: https://scholar.harvard.edu/files/lucamaini/files/reference_pricing_as_a_deterrent_to_entry.pdf
12. Vogler S, Zimmermann N, Babar ZU. Price comparison of high-cost originator medicines in European countries. Expert Rev Pharmacoecon Outcomes Res. (2017) 17:221–30. doi: 10.1080/14737167.2016.1223543
14. Csanádi M, Kaló Z, Prins CP, Grélinger E, Kiss AM, Fricke F-U, et al. The implications of external price referencing on pharmaceutical list prices in Europe. Health Policy Technol. (2018) 7:243–50. doi: 10.1016/j.hlpt.2018.07.005
15. Németh G, Szigeti S, Pusztai Z. Improved effectiveness of generic medicine markets in Hungary. Analysis and recommendations. WHO Regional Office for Europe. World Health Organization. (2015). Available online at: https://apps.who.int/iris/handle/10665/170483
17. Mitkova Z, Manova M, Savova A, Peneva A, Mitkov J, Tkachova O, et al. Statins utilization and price variations-comparison between Ukraine and Bulgaria. Biomed Res. (2018) 29:3398–401. doi: 10.4066/biomedicalresearch.29-18-992
18. Aaron KJ, Colantonio LD, Deng L, Judd SE, Locher JL, Safford SS, et al. Cardiovascular health and healthcare utilization and expenditures among medicare beneficiaries: the reasons for geographic and racial differences in stroke (REGARDS) study. J Am Heart Assoc. (2017) 6:e005106. doi: 10.1161/JAHA.116.005106
19. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels (2017). Available online at: http://www.ehnheart.org/images/CVD-statistics-report-August-2017.pdf
20. Export Market Research. The Romanian Health Care Sector, Commercial Opportunities and Possibilities for Cooperation. (2019) Available online at: https://www.rvo.nl/sites/default/files/2019/02/The-Romanian-health-care-sector.pdf
22. Williams B, Mancia G, Spiering W, Rosei E, Azizi M, Burnier M, et al. ESC Scientific Document Group ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. (2018) 33:3021–104. doi: 10.1093/eurheartj/ehy339
23. Hypertension in adults: diagnosis and management. NICE. (2019). Available online at: www.nice.org.uk/guidance/ng136
24. Ministerial Decision No G5(a) 90552/ Government Gazette B 3890/2016 on the setting of pharmaceutical prices, as amended by Ministerial Decisions G5(a) 97012/Government Gazette B 4215/2016 and G5(a) 11601/Government Gazette B 445/2017.
25. NORME din 28 martie 2017 privind modul de calcul?iprocedura de aprobare a pre?urilormaximale ale medicamentelor de uzumanPublicatăîn MONITORUL OFICIAL nr. 215 din 29 martie 2017; Aprobateprin ORDINUL nr. 368 din 28 martie 2017, publicatînMonitorulOficial nr. 215 din 29 martie 2017
26. Ordinance on the terms, rules and procedure for regulation and registration of prices for medicinal products, Effective 30 April 2013 Adopted by Council of Ministers Decree No. 97 of 19 April 2013, amended and supplemented, SG 102 of 22 December 2017. Available online at: http://www.ncpr.bg/images/REGULATIONS/2017/20.02.2017/Naredba_tseni_NCPR_24.01.2017-eng.pdf
27. Act No. 363/2011 Coll. on the scope and conditions of payments for medicines, medical devices and dietetic foods from public health insurance and amending certain acts, as amended. http://www.zakonypreludi.sk/zz/2011-363
28. National Council on prices and reimbursement of medicinal products. Registers PDL (2017). Annex 1. Available online at: https://portal.ncpr.bg/registers/pages/register/archive.xhtml
29. Ministerstvo zdravotníctva. Available online at: http://www.health.gov.sk/?kategorizacia-a-ceny
30. Yπoϵργεío Yγεíας/Ministry of health. Available online at: http://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn
31. Casa Nationalâ de Asigurâri de Sânâtata/ National Health Insurance Fund. Available online at: http://www.cnas.ro/category/lista-medicamentelor.html
32. Tsakanikas A, Athanasiadis A, Pavlouet G. The Pharmaceutical Market in Greece: Facts & Figures 2017. Foundation for Economic and Industrial. Hellenic Association of Pharmaceutical Companies. (2017). Available online at: http://iobe.gr/docs/research/en/RES_05_A_27022018_REP_ENG.PDF
35. European medicine price database EURIPID. Available online at: https://www.euripid.eu/aboutus
36. Kanavos P, Fontrier A, Gill J, Efthymiadou O. Does external reference pricing deliver what it promises? Evidence on its impact at national level. Eur J Health Econ. (2020) 21:129–51. doi: 10.1007/s10198-019-01116-4
39. Wettstein DJ, Boes S. Effectiveness of national pricing policies for patent-protected pharmaceuticals in the OECD: a systematic literature review. Appl Health Econ Health Policy. (2019) 17:143–62. doi: 10.1007/s40258-018-0437-z
40. Ferrario A, Arāja D, Bochenek T, Catic T, Danko D, Dimitrova M, et al. The implementation of managed entry agreements in central and eastern europe: findings and implications. Pharmacoeconomics. (2017) 35:1271–85. doi: 10.1007/s40273-017-0559-4
43. Håkonsen H, Horn AM, Toverud EL. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004? Health Policy. (2009) 90:277–85. doi: 10.1016/j.healthpol.2008.09.018
44. Annual reports of National Council of prices reimbursement (2018) Available online at: www.ncpr.bg
45. Stoimenova A, Penkov S, Savova A, Manova M, Petrova G. Generic policy in Bulgaria: a policy of failure or success? Biotechnol Biotechnol Equip. (2016) 30:1031–7. doi: 10.1080/13102818.2016.1208061
46. Greece Health Care and Long-Term Care Systems. An Excerpt from the Joint Report on Health Care and Long-Term Care Systems and Fiscal Sustainability. Vol. 37. Institutional Paper (2016). p. 14–221. doi: 10.2765/680422
47. Leopold C, Mantel-Teeuwisse AK, Vogler S, de Joncheere K, Laing R, Leufkens HG. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy. (2013) 112:20916. doi: 10.1016/j.healthpol.2013.08.012
48. Brodszky V, Beretzky Z, Baji P, Rencz F, Péntek M, Rotar A, et al. Cost-of-illness studies in nine Central and Eastern European countries. Eur J Health Econ. (2019) 20:155–72. doi: 10.1007/s10198-019-01066-x
Keywords: ACE- inhibitors, AT1-receptor blockers, manufacturer price, retail price, price difference
Citation: Mitkova Z, Vasileva M, Savova A, Manova M, Terezova S and Petrova G (2020) Comparison of Cardiovascular Medicines Prices in Four European Countries. Front. Public Health 8:433. doi: 10.3389/fpubh.2020.00433
Received: 22 May 2020; Accepted: 15 July 2020;
Published: 21 August 2020.
Edited by:Nemanja Rancic, Faculty of Medicine, Military Medical Academy, Serbia
Reviewed by:Stefano Omboni, Istituto Italiano di Telemedicina, Italy
Simon Grima, University of Malta, Malta
Svetlana Radevic, University of Kragujevac, Serbia
Copyright © 2020 Mitkova, Vasileva, Savova, Manova, Terezova and Petrova. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zornitsa Mitkova, firstname.lastname@example.org